Cosmos Health's Cana Laboratories Signs 5-Year EU Manufacturing Deal With Pharmex To Produce 2.86M Units Of Prescription Dermatology Products
Cosmos Health Inc COSM | 0.00 |
Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that, through its wholly owned subsidiary Cana Laboratories S.A. ("Cana"), it has entered into a five-year contract manufacturing agreement with Pharmex S.A. ("Pharmex") to produce three pharmaceutical products.
Under the agreement, Cana will manufacture the following products for Pharmex at its EU-GMP-licensed, EMA-certified facility, with combined volumes of approximately 2.86 million units over the five-year term.
| Product | Active Ingredient | Pharmaceutical Form | Annual Units | Five-Year Total |
| BETAFUSIN® | Betamethasone, Fusidic Acid | Cream | 450,000 | 2,250,000 |
| BOTAFEX® | Minoxidil | Cutaneous Solution | 65,000 | 325,000 |
| BUDESODERM® | Budesonide | Cream / Cutaneous Solution | 57,000 | 285,000 |
| Total | 572,000 | 2,860,000 |
The agreement reinforces Cosmos Health's role as a contract manufacturer of pharmaceutical products and supports higher utilization of its EU manufacturing capacity. By leveraging Cana's licensed production capabilities, the Company aims to deepen its long-term manufacturing partnerships and strengthen recurring revenue from its higher-margin contract manufacturing activities.
Founded in 1981, Pharmex is a Greek pharmaceutical company with over 40 years in medicinal products and dermocosmetics. It develops and produces its own products and serves as the exclusive local distributor for international partners. Pharmex products are available in more than 20 countries across Europe, the Middle East, Asia, Africa and Latin America.